Novocure (NVCR) Misses Q1 EPS by 10c, Miss on Revenues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
NovoCure Ltd. (NVCR) PT Raised to $31 at Deutsche Bank
April 27, 2018 7:46 AM EDTDeutsche Bank raised its price target on NovoCure Ltd. (NASDAQ: NVCR) to $31.00 (from $29.00) while maintaining a Buy rating.
Analyst Gregg Gilbert commented, "NVCR reported strong patient uptake in GBM globally, with US contributing a majority of the increase in patient numbers... More
